Carnley Norman
About Carnley Norman
Carnley Norman serves as the Vice President and Head of Global Manufacturing Sciences & Technology (MSAT) at Kite Pharma, where he supports viral vector and cell-therapy commercial manufacturing. He has extensive experience in the biopharmaceutical industry, having held various leadership roles at companies such as Novartis, MedImmune, and KBI Biopharma.
Current Role at Kite Pharma
Carnley Norman serves as the Vice President and Head of Global Manufacturing Sciences & Technology (MSAT) at Kite Pharma. In this role, he supports viral vector and cell-therapy commercial manufacturing. He leads the implementation of new technology within the MSAT organization and oversees process validation and comparability efforts, ensuring the effectiveness and efficiency of manufacturing processes.
Previous Experience in Biopharmaceuticals
Prior to his current position, Carnley Norman held several roles in the biopharmaceutical industry. He worked at KBI Biopharma in various capacities, including Vice President of Global Process Development and Vice President of Manufacturing Operations. His experience also includes positions at Novartis Vaccines and Diagnostics as Senior Principal Scientist and at MedImmune as Scientist II and Senior Scientist in Manufacturing Sciences & Technology.
Educational Background in Chemical Engineering
Carnley Norman earned his Ph.D. in Chemical Engineering from North Carolina State University, where he studied from 1994 to 2000. He also holds a Bachelor of Science degree in Chemical Engineering from the Georgia Institute of Technology, completed between 1992 and 1994. Additionally, he obtained a Bachelor of Science in Chemistry from Morehouse College, where he studied from 1988 to 1992.
Career Progression in Manufacturing Sciences
Carnley Norman's career in manufacturing sciences began at Merck as a Vaccine Process Engineer from 2000 to 2004. He then transitioned to Amgen as a Principal Engineer, where he worked until 2009. Following this, he joined MedImmune, where he progressed through various roles in manufacturing sciences, contributing to advancements in the field before moving to KBI Biopharma.